Novel action and mechanism of auranofin in inhibition of vascular endothelial growth factor receptor-3-dependent lymphangiogenesis

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 7, 2014, Pages 946-954

  Chen, Xiaodong ^a,b   Zhou, Huanjiao Jenny ^a,b   Huang, Qunhua ^b   Lu, Lin ^a,b   Min, Wang ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Auranofin; Lymphangiogenesis; Thioredoxin reductase; Vascular endothelial growth factor receptor 3

Indexed keywords

AURANOFIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 14; THIOREDOXIN REDUCTASE; VASCULOTROPIN RECEPTOR 3;

APOPTOSIS; CELL LINE; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; HUMAN; LYMPHANGIOGENESIS; LYSOSOME; METABOLISM; SIGNAL TRANSDUCTION;

APOPTOSIS; AURANOFIN; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIAL CELLS; HUMANS; LYMPHANGIOGENESIS; LYSOSOMES; MITOGEN-ACTIVATED PROTEIN KINASE 14; NF-KAPPA B; SIGNAL TRANSDUCTION; THIOREDOXIN-DISULFIDE REDUCTASE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84905657679     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140610102651     Document Type: Article

References (39)

1. Finkelstein, A.E.; Walz, D.T.; Batista, V.; Mizraji, M.; Roisman, F.; Misher, A. Auranofin. New oral gold compound for treatment of rheumatoid arthritis. Ann. Rheum. Dis., 1976, 35 (3), 251-257.
2. Glennas, A.; Kvien, T.K.; Andrup, O.; Clarke-Jenssen, O.; Karstensen, B.; Brodin, U. Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. British J. Rheum., 1997, 36(8), 870-877.
3. Gabbiani, C.; Messori, L. Protein targets for anticancer gold compounds: Mechanistic inferences. Anti-Cancer Agents Curr. Med. Chem., 2011, 11 (10), 929-939.
4. Casini, A.; Messori, L. Molecular mechanisms and proposed targets for selected anticancer gold compounds. Curr. Topics in Med. Chem., 2011, 11(21), 2647-2660.
5. Matsubara, T.; Ziff, M. Inhibition of human endothelial cell proliferation by gold compounds. J.Clin. Invest.,1987, 79 (5), 1440-1446.
6. Madeira, J.M.; Gibson, D.L.; Kean, W.F.; Klegeris, A. The biological activity of auranofin: Implications for novel treatment of diseases. Inflammopharmacology, 2012, 20 (6), 297-306.
7. Baluk, P.; Yao, L.C.; Feng, J.; Romano, T.; Jung, S.S. Schreiter, J.L.; Yan, L.; Shealy, D.J.; McDonald, D.M. TNF-alphadrives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice. J. Clin. Invest., 2009, 119 (10), 2954-2964.
8. Stacker, S.A.; Caesar, C.; Baldwin, M.E.; Thornton, G. E.; Williams, R.A.; Prevo, R.; Jackson, D.G.; Nishikawa, S.; Kubo, H.; Achen, M.G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med., 2001, 7(2), 186-191.
9. Mandriota, S.J.; Jussila, L.; Jeltsch, M.; Compagni, A.; Baetens, D. Prevo, R.; Banerji, S.; Huarte, J.; Montesano, R.; Jackson, D.G. Orci, L.; Alitalo, K.; Christofori, G.; Pepper, M.S. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. Embo. J., 2001, 20(4), 672-682.
10. Vass, D.G.; Hughes, J.; Marson, L.P. Restorative and rejection-associated lymphangiogenesis after renal transplantation: Friend or foe? Transplantation, 2009, 88(11), 1237-1239.
11. Bruyere, F.; Noel, A., Lymphangiogenesis: In vitro and in vivo models. FASEB J., 2010, 24(1), 8-21.
12. Halin, C.; Detmar, M. Inflammation, angiogenesis, and lymphangiogenesis. Methods Enzymol., 2008, 445, 1-25.
13. Breiteneder-Geleff, S.; Soleiman, A.; Horvat, R.; Amann, G. Kowalski, H.; Kerjaschki, D. Podoplanin--a specific marker for lymphatic endothelium expressed in angiosarcoma. Verh. Dtsch. Ges. Pathol., 1999, 83, 270-275.
14. Banerji, S.; Ni, J.; Wang, S.X.; Clasper, S.; Su, J.; Tammi, R. Jones, M.; Jackson, D.G. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol., 1999, 144 (4), 789-801.
15. Karpanen, T.; Alitalo, K. Molecular biology and pathology of lymphangiogenesis. Annu. Rev. Pathol., 2008, 3, 367-397.
16. Tammela, T.; Alitalo, K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell, 2010, 140 (4), 460-476.
17. Kaipainen, A.; Korhonen, J.; Mustonen, T.; Van Hinsbergh, V.W.; Fang, G. H.; Dumont, D.; Breitman, M.; Alitalo, K. Expression of the fmslike tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA, 1995, 92(8), 3566-3570.
18. Valtola, R.; Salven, P.; Heikkila, P.; Taipale, J.; Joensuu, H. Rehn, M.; Pihlajaniemi, T.; Weich, H.; DeWaal, R.; Alitalo, K. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J.Pathol., 1999, 154(5), 1381-1390.
19. Paavonen, K.; Puolakkainen, P.; Jussila, L.; Jahkola, T.; Alitalo, K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol., 2000, 156 (5), 1499-1504.
20. Jones, D.; Min, W. An overview of lymphatic vessels and their emerging role in cardiovascular disease. J. Cardiovasc. Dis. Res., 2011, 2(3), 141-152.
21. Stacker, S.A.; Williams, S.P.; Karnezis, T. Shayan, R.; Fox, S.B.; Achen, M.G. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev. Cancer, 2014, 14 (3), 159-172.
22. Jones, D.; Li, Y.; He, Y.; Xu, Z.; Chen, H.; Min, W. Mirtron MicroRNA-1236 inhibits VEGFR-3 signaling during inflammatory lymphangiogenesis. Arterioscler. Thromb. Vasc. Biol., 2012, 32 (3), 633-642.
23. Jones, D.; Xu, Z.; Zhang, H.; He, Y.; Kluger, M.S.; Chen, H.; Min, W. Functional analyses of the nonreceptor kinase bone marrow kinase on the X chromosome in vascular endothelial growth factor-induced lymphangiogenesis. Arterioscler. Thromb. Vasc. Biol., 2010, 30(12), 2553-2561.
24. Zhou, H.J.; Chen, X.; Huang, Q.; Liu, R.; Zhang, H.; Wang, Y. Jin, Y.; Liang, X.; Lu, L.; Xu, Z.; Min, W. AIP1 mediates vascular endothelial cell growth factor receptor-3-dependent angiogenic and lymphangiogenic responses. Arterioscler. Thromb. Vasc. Biol., 2014, 34(3), 603-615.
25. Zhang, H.; Du, Y.; Zhang, X.; Lu, J.; Holmgren, A. Glutaredoxin 2 reduces both thioredoxin 2 and thioredoxin 1 and protects cells from apoptosis induced by auranofin and 4-Hydroxynonenal. Antioxid. Redox. Signal, 2014. [Epub ahead of print].
26. Park, S.J.; Kim, I.S. The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br. J. Pharmacol., 2005, 146(4), 506-513.
27. Nakaya, A.; Sagawa, M.; Muto, A.; Uchida, H.; Ikeda, Y.; Kizaki, M. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity. Leukemia Res., 2011, 35(2), 243-249.
28. Powis, G.; Montfort, W.R. Properties and biological activities of thioredoxins. Annu. Rev. Pharmacol.Toxicol., 2001, 41, 261-295.
29. Lee, S.; Kim, S.M.; Lee, R.T. Thioredoxin and Thioredoxintarget proteins: From molecular mechanisms to functional significance. Antioxid. Redox. Signal., 2013, 18(10), 1165-207.
30. Lu, J.; Holmgren, A. Thioredoxin system in cell death progression. Antioxid. Redox. Signal, 2012, 17(12), 1738-1747.
31. Pajusola, K.; Aprelikova, O.; Pelicci, G.; Weich, H.; Claesson-Welsh, L.; Alitalo, K. Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene, 1994, 9(12), 3545-3555.
32. Bando, H.; Brokelmann, M.; Toi, M.; Alitalo, K.; Sleeman, J.P.; Sipos, B. Grone, H.J.; Weich, H.A. Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues. Int. J. Cancer, 2004, 111(2), 184-191.
33. Li, M.; Khambu, B.; Zhang, H.; Kang, J.H.; Chen, X.; Chen, D. Vollmer, L.; Liu, P.Q.; Vogt, A.; Yin, X.M. Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity. J. Biol. Chem., 2013, 288 (50), 35769-35780.
34. Arner, E.S.; Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J.Biochem., 2000, 267(20), 6102-6109.
35. Sakurai, A.; Yuasa, K.; Shoji, Y.; Himeno, S.; Tsujimoto, M. Kunimoto, M.; Imura, N.; Hara, S. Overexpression of thioredoxin reductase 1 regulates NF-kappa B activation. J. Cell Physiol., 2004, 198 (1), 22-30.
36. Go, Y.M.; Roede, J.R.; Walker, D.I.; Duong, D.M.; Seyfried, N.T. Orr, M.; Liang, Y.; Pennell, K.D.; Jones, D.P. Selective targeting of the cysteine proteome by thioredoxin and glutathione redox systems. Mol. Cell Proteomics, 2013, 12(11), 3285-3296.
37. Nakayama, M.; Berger, P. Coordination of VEGF receptor trafficking and signaling by coreceptors. Exp. Cell Res., 2013, 319 (9), 1340-1307.
38. Benedito, R.; Rocha, S.F.; Woeste, M. Zamykal, M.; Radtke, F.; Casanovas, O.; Duarte, A.; Pytowski, B. Adams, R.H. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature, 2012, 484(7392), 110-114.
39. Nakayama, M.; Nakayama, A.; Van Lessen, M.; Yamamoto, H.; Hoffmann, S.; Drexler, H.C.; Itoh, N. Hirose, T.; Breier, G.; Vestweber, D.; Cooper, J.A.; Ohno, S. Kaibuchi, K.; Adams, R.H. Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat. Cell, Biol., 2013, 15(3), 249-260.